ABT: 10-Q financial filing

Item 8.01 of its Current Report on Form 8-K filed on August 20, 2026, including those described below (as of September 30, 2026, except where noted below). While it is not feasible to predict the outcome of such pending claims, proceedings, and investigations with certainty, management is of the opinion that their ultimate resolution should not have a material adverse effect on Abbott's financial position, cash flows, or results of operations. In the 2025 10-K, Abbott reported that the United States Department of Justice (DOJ), through the United States Attorney’s Office for the Western District of Michigan, was conducting an investigation related to Abbott’s manufacturing of powdered infant formula, and that the DOJ intervened, in part, in a civil qui tam lawsuit previously filed under seal against Abbott by three private individuals in the U.S. District Court for the Western District of Michigan. The qui tam lawsuit related to Abbott’s U.S. manufacturing of powdered infant formula products. The Attorneys General of several states filed a consolidated complaint-in-intervention in the same lawsuit. In September 2026, Abbott reached an agreement to resolve the DOJ investigations and the aforementioned complaints, pursuant to which Abbott agreed to pay approximately $385 million, plus attorneys’ fees and accrued interest, to resolve all claims. The settlement does not represent any finding of fault or liability, and no evidence was found that Abbott infant formula products caused the illnesses or deaths that prompted Abbott’s voluntary recall in 2022. 34 Table of Contents Item 2. Unregistered Sales of Equity Securities and Use of Proceeds (c) Issuer Purchases of Equity Securities Period (a) Total Number of Shares (or Units) Purchased (b) Average Price Paid per Share (or U